Si-Bone (NSDQ:SIBN) last week closed an initial public offering that brought in much more than anticipated for its iFuse sacroiliac implant.
The Santa Clara, Calif.-based company priced the 7.2-million-share flotation at $15 per share, which at $108 million would have topped its initial range of about $90 million to nearly $104 million (which itself would have beaten the $99 million target set in its initial IPO registration in September).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,